Lakefront Biotherapeutics (LKFT) Raw Materials (2021 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Raw Materials for 5 consecutive years, with $25.6 million the latest figure, recorded in Q4 2025.

• Quarterly Raw Materials fell 56.06% year-over-year to $25.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.6 million (down 56.06% YoY) and the FY2025 annual result came in at $25.6 million, down 56.06% from the prior year.
• Raw Materials slipped to $25.6 million in Q4 2025 per LKFT's latest filing, from $58.3 million in the prior quarter.
• Over the last five years, Raw Materials for LKFT reached as high as $62.9 million in Q4 2023 and fell as low as $16.3 million in Q4 2021.
• A 5-year average of $41.5 million and a median of $44.5 million in 2022 frame the typical range for Raw Materials.
• Annual changes were most pronounced in 2022 — Raw Materials jumped 172.25% — and 2025, when it tumbled 56.06%.
• Year by year, Raw Materials stood at $16.3 million in 2021, then jumped by 172.25% to $44.5 million in 2022, then soared by 41.44% to $62.9 million in 2023, then retreated by 7.37% to $58.3 million in 2024, then slumped by 56.06% to $25.6 million in 2025.
• According to Business Quant data, Raw Materials over the past three periods registered $25.6 million, $58.3 million, and $62.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.